Language
BiondVax Shares Leap Premarket on Antibody Licensing Deal

News

HomeHome / News / BiondVax Shares Leap Premarket on Antibody Licensing Deal
search
RECENT NEWS

Apr 29, 2023

HER2

Jul 09, 2023

Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix

Jun 21, 2023

Cell Counting Market size is projected to grow at a CAGR of 7.1%

Aug 20, 2023

Effects of anoxic prognostic model on immune microenvironment in pancreatic cancer

Jun 03, 2023

Granulocyte colony

SEND YOUR INQUIRY
SUBMIT

May 03, 2023

BiondVax Shares Leap Premarket on Antibody Licensing Deal

By Colin Kellaher Shares of BiondVax Pharmaceuticals rose more than 30% in

By Colin Kellaher

Shares of BiondVax Pharmaceuticals rose more than 30% in premarket trading Monday after the biotechnology company said it had signed a license agreement for the development and commercialization of an antibody targeting cytokine interleukin-17 for the treatment of autoimmune and inflammatory diseases.

BiondVax shares were recently up at $2.26 in premarket trading. The stock closed Friday at $1.70, down about 43% for the year to date.

The Jerusalem-based company said the agreement, part of its collaboration with the Max Planck Society and the University Medical Center Gottingen, covers the antibody in all potential indications, starting with psoriasis and psoriatic arthritis.

Write to Colin Kellaher at [email protected]

Major cryptocurrencies sank on Monday, after the Securities and Exchange Commission charged the world's largest crypto exchange, Binance Holdings Inc., and its founder Changpeng Zhao with 13 securities law violations.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.